Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.

The entities involved

• Nasdaq →

  American fully electronic stock exchange

  • MicroVision, Inc. successfully completed key steps in its listing process on Nasdaq, including SEC declaration and prospectus availability.22:37
  • General Motors is planning to move its stock listing from the New York Stock Exchange to Nasdaq.22:31
• Moderna →

  American biotechnology company

  • Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Sun 12:39
  • Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.Sat 22:35
• FDA →
  • HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.21:18
  • The National Center for PTSD provides data on PTSD in the US while university researchers develop FDA-cleared treatments.21:09
• Regeneron Pharmaceuticals →

  American pharmaceutical company

  Nothing else this week.

Related events

• Praxis Precision Medicines and Relay Therapeutics were listed on the Nasdaq stock exchange on October 1, 2026.Sun 04:37
• Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Oct 18